302 related articles for article (PubMed ID: 19332770)
1. Role of a second chemotherapy in recurrent malignant glioma patients who progress on bevacizumab.
Quant EC; Norden AD; Drappatz J; Muzikansky A; Doherty L; Lafrankie D; Ciampa A; Kesari S; Wen PY
Neuro Oncol; 2009 Oct; 11(5):550-5. PubMed ID: 19332770
[TBL] [Abstract][Full Text] [Related]
2. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence.
Norden AD; Young GS; Setayesh K; Muzikansky A; Klufas R; Ross GL; Ciampa AS; Ebbeling LG; Levy B; Drappatz J; Kesari S; Wen PY
Neurology; 2008 Mar; 70(10):779-87. PubMed ID: 18316689
[TBL] [Abstract][Full Text] [Related]
3. Bevacizumab in recurrent high-grade pediatric gliomas.
Narayana A; Kunnakkat S; Chacko-Mathew J; Gardner S; Karajannis M; Raza S; Wisoff J; Weiner H; Harter D; Allen J
Neuro Oncol; 2010 Sep; 12(9):985-90. PubMed ID: 20363768
[TBL] [Abstract][Full Text] [Related]
4. Retrospective study of carmustine or lomustine with bevacizumab in recurrent glioblastoma patients who have failed prior bevacizumab.
Rahman R; Hempfling K; Norden AD; Reardon DA; Nayak L; Rinne ML; Beroukhim R; Doherty L; Ruland S; Rai A; Rifenburg J; LaFrankie D; Alexander BM; Huang RY; Wen PY; Lee EQ
Neuro Oncol; 2014 Nov; 16(11):1523-9. PubMed ID: 24958095
[TBL] [Abstract][Full Text] [Related]
5. Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas.
Desjardins A; Reardon DA; Herndon JE; Marcello J; Quinn JA; Rich JN; Sathornsumetee S; Gururangan S; Sampson J; Bailey L; Bigner DD; Friedman AH; Friedman HS; Vredenburgh JJ
Clin Cancer Res; 2008 Nov; 14(21):7068-73. PubMed ID: 18981004
[TBL] [Abstract][Full Text] [Related]
6. Treatment of children with recurrent high grade gliomas with a bevacizumab containing regimen.
Parekh C; Jubran R; Erdreich-Epstein A; Panigrahy A; Bluml S; Finlay J; Dhall G
J Neurooncol; 2011 Jul; 103(3):673-80. PubMed ID: 21038110
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of stereotactic radiosurgery and adjuvant bevacizumab in patients with recurrent malignant gliomas.
Cuneo KC; Vredenburgh JJ; Sampson JH; Reardon DA; Desjardins A; Peters KB; Friedman HS; Willett CG; Kirkpatrick JP
Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):2018-24. PubMed ID: 21489708
[TBL] [Abstract][Full Text] [Related]
8. The role of salvage reirradiation for malignant gliomas that progress on bevacizumab.
Torcuator RG; Thind R; Patel M; Mohan YS; Anderson J; Doyle T; Ryu S; Jain R; Schultz L; Rosenblum M; Mikkelsen T
J Neurooncol; 2010 May; 97(3):401-7. PubMed ID: 19838627
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of bevacizumab plus irinotecan in children with recurrent low-grade gliomas--a Pediatric Brain Tumor Consortium study.
Gururangan S; Fangusaro J; Poussaint TY; McLendon RE; Onar-Thomas A; Wu S; Packer RJ; Banerjee A; Gilbertson RJ; Fahey F; Vajapeyam S; Jakacki R; Gajjar A; Goldman S; Pollack IF; Friedman HS; Boyett JM; Fouladi M; Kun LE
Neuro Oncol; 2014 Jan; 16(2):310-7. PubMed ID: 24311632
[TBL] [Abstract][Full Text] [Related]
10. Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma.
Sathornsumetee S; Desjardins A; Vredenburgh JJ; McLendon RE; Marcello J; Herndon JE; Mathe A; Hamilton M; Rich JN; Norfleet JA; Gururangan S; Friedman HS; Reardon DA
Neuro Oncol; 2010 Dec; 12(12):1300-10. PubMed ID: 20716591
[TBL] [Abstract][Full Text] [Related]
11. Bevacizumab plus irinotecan in recurrent malignant glioma shows high overall survival in a multicenter retrospective pooled series of the Spanish Neuro-Oncology Research Group (GEINO).
Gil MJ; de Las Peñas R; Reynés G; Balañá C; Peréz-Segura P; García-Velasco A; Mesia C; Gallego O; Fernández-Chacón C; Martínez-García M; Herrero A; Andrés R; Benavides M; Quintanar T; Pérez-Martin X
Anticancer Drugs; 2012 Jul; 23(6):659-65. PubMed ID: 22634799
[TBL] [Abstract][Full Text] [Related]
12. Bevacizumab is active as a single agent against recurrent malignant gliomas.
Agha CA; Ibrahim S; Hassan A; Elias DA; Fathallah-Shaykh HM
Anticancer Res; 2010 Feb; 30(2):609-11. PubMed ID: 20332478
[TBL] [Abstract][Full Text] [Related]
13. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma.
Vredenburgh JJ; Desjardins A; Herndon JE; Dowell JM; Reardon DA; Quinn JA; Rich JN; Sathornsumetee S; Gururangan S; Wagner M; Bigner DD; Friedman AH; Friedman HS
Clin Cancer Res; 2007 Feb; 13(4):1253-9. PubMed ID: 17317837
[TBL] [Abstract][Full Text] [Related]
14. Treatment with bevacizumab plus carboplatin for recurrent malignant glioma.
Thompson EM; Dosa E; Kraemer DF; Neuwelt EA
Neurosurgery; 2010 Jul; 67(1):87-93. PubMed ID: 20559095
[TBL] [Abstract][Full Text] [Related]
15. Irinotecan and bevacizumab in progressive primary brain tumors, an evaluation of efficacy and safety.
Kang TY; Jin T; Elinzano H; Peereboom D
J Neurooncol; 2008 Aug; 89(1):113-8. PubMed ID: 18438609
[TBL] [Abstract][Full Text] [Related]
16. Phase I study of panobinostat in combination with bevacizumab for recurrent high-grade glioma.
Drappatz J; Lee EQ; Hammond S; Grimm SA; Norden AD; Beroukhim R; Gerard M; Schiff D; Chi AS; Batchelor TT; Doherty LM; Ciampa AS; Lafrankie DC; Ruland S; Snodgrass SM; Raizer JJ; Wen PY
J Neurooncol; 2012 Mar; 107(1):133-8. PubMed ID: 21984064
[TBL] [Abstract][Full Text] [Related]
17. Treatment with bevacizumab and irinotecan for recurrent high-grade glial tumors.
Bokstein F; Shpigel S; Blumenthal DT
Cancer; 2008 May; 112(10):2267-73. PubMed ID: 18327820
[TBL] [Abstract][Full Text] [Related]
18. Lack of efficacy of bevacizumab plus irinotecan in children with recurrent malignant glioma and diffuse brainstem glioma: a Pediatric Brain Tumor Consortium study.
Gururangan S; Chi SN; Young Poussaint T; Onar-Thomas A; Gilbertson RJ; Vajapeyam S; Friedman HS; Packer RJ; Rood BN; Boyett JM; Kun LE
J Clin Oncol; 2010 Jun; 28(18):3069-75. PubMed ID: 20479404
[TBL] [Abstract][Full Text] [Related]
19. A phase II trial with bevacizumab and irinotecan for patients with primary brain tumors and progression after standard therapy.
Møller S; Grunnet K; Hansen S; Schultz H; Holmberg M; Sorensen M; Poulsen HS; Lassen U
Acta Oncol; 2012 Jul; 51(6):797-804. PubMed ID: 22548369
[TBL] [Abstract][Full Text] [Related]
20. Outcome after bevacizumab clinical trial therapy among recurrent grade III malignant glioma patients.
Reardon DA; Herndon JE; Peters K; Desjardins A; Coan A; Lou E; Sumrall A; Turner S; Sathornsumetee S; Rich JN; Boulton S; Lipp ES; Friedman HS; Vredenburgh JJ
J Neurooncol; 2012 Mar; 107(1):213-21. PubMed ID: 21997879
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
